A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid Tumors

A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (HLX10) in Combination With Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection (HLX04) in Patients With Advanced Solid Tumors

This is a single-center, open-label, dose-escalation Phase I clinical trial to evaluate the safety and the tolerability of HLX10-HLX04 combination therapy in patients with advanced solid tumors after failure of standard of care.

Study Overview

• Status: Unknown
• Conditions: Solid Tumor
• Intervention / Treatment: Drug: HLX04; Drug: HLX10

• Study Type: Interventional
• Enrollment (Anticipated): 30
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Shanghai, China
    • Recruiting
    • Shanghai East Hospital
    • Contact: Jin Li, MD; Email: lijin@csco.org.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Age ≥18 years, male or female
2. Patient with histologically or cytologically confirmed advanced malignant solid tumors who have failed standard of care, or has no standard-of-care therapy or are not suitable for standard of care at the present stage;
3. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1；
4. Life expectancy greater than 3 months;
5. Patient must have at least one measurable tumor lesion as defined by RECIST v1.1; the lesion concerned must not be a bone metastasis if only one target lesion is present;
6. Has adequate organ functions;
7. If the subject is a patient with hepatocellular carcinoma, Child-Pugh classification must be A.
8. A qualified patient (male or female) of childbearing potential must agree to use reliable contraceptive methods (hormonal, or barrier method or abstinence) for the course of the study and through at least 6 months after the last dose; a female patient of childbearing potential must have negative blood pregnancy test within 7 days prior to enrollment;
9. The subject must give his/her informed consent to this study prior to the trial, and voluntarily sign a written informed consent form.

Exclusion Criteria:

1. Histopathological confirmed head and neck cancer or squamous-cell lung cancer, or bleeding tendency in the tumor lesion judged by the investigator;
2. Has received antitumor therapy like radiotherapy, chemotherapy, targeted therapy, endocrinal therapy or immunotherapy, or other clinical study drug therapy within 4 months prior to the initial drug administration;
3. Has received a surgical operation on major viscera or experienced apparent trauma within 4 weeks from the initial drug administration, or experienced subcutaneous venous access device implantation within 7 days;
4. The adverse reactions which occurred in the previous antitumor treatment were not recovered to ≤ grade 1 based on CTCAE 4.03 assessment (except for hair loss);
5. Evidences of metastatic lesion in the patient's central nervous system;
6. Previously experienced ≥ grade 3 immune-related adverse event during immunotherapy;
7. Active, or history of autoimmune disease which may relapse (for example, systemic lupus erythematosus, rheumatoid arthritis, vasculitis, etc.);
8. Currently having or have had interstitial lung disease;
9. Uncontrollable active infection(s);
10. History of immunodeficiency, including HIV antibody positive;
11. Known active hepatitis B; or hepatitis C virus infections;
12. Has bleeding tendency;
13. History of severe cardiovascular diseases;

14. Known gastrointestinal diseases as follows:

    Gastrointestinal perforation, abdominal fistula or abdominal abscess within 6 months before signing the informed consent; History of poorly controlled or recurrent inflammatory bowel disease; Active peptic ulcers, or > moderate esophageal varices;

15. Known hypersensitivity to Bevacizumab, or other anti-PD-1, anti-PD-L1 monoclonal antibody agents;
16. Pregnant or breastfeeding female.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: HLX04+HLX10; HLX10, at three dose levels (1, 3, 10 mg/kg), to be intravenously injected once every two weeks; HLX04, at a fixed dose of 5 mg/kg, intravenously injected once every two weeks; Study drugs given in combination for up to 2 years or until the disease gets worse, whichever comes first.	Drug: HLX04; Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection; Drug: HLX10; Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum Tolerated Dose (MTD) of HLX04 plus HLX10 in patients with advanced solid tumors	The MTD is the dose with toxicity rate (estimated by isotonic regression) most approximate to the target one (30%).	28 days
Dose Limiting Toxicity (DLT) of HLX04 plus HLX10 in patients with advanced solid tumors	DLT is defined as the occurrence of the following adverse events (unless judged by the investigator to be definitely unrelated to HLX04 or HLX10) within Cycle 1 (i.e., from Cycle 1 Day 1 to Cycle 1 Day 28)	28 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
PK parameters of the HLX04 plus HLX10 therapy in patients with advanced solid tumors	Peak Plasma Concentration (Cmax) for single dose and multiple doses	Day 1 of treatment up to 2 years
PK parameters of the HLX04 plus HLX10 therapy in patients with advanced solid tumors	Area under the plasma concentration versus time curve (AUC) for single dose and multiple doses	Day 1 of treatment up to 2 years
Objective Response Rate (ORR) of HLX04 plus HLX10 in patients with advanced solid tumors	ORR determined by RECIST criteria	Day 1 of treatment up to 2 years
Disease Control Rate (DCR) of HLX04 plus HLX10 in patients with advanced solid tumors	DCR determined by RECIST criteria	Day 1 of treatment up to 2 years
Duration of Response (DOR) of HLX04 plus HLX10 in patients with advanced solid tumors	DOR determined by RECIST criteria	Day 1 of treatment up to 2 years
Progression-Free Survival (PFS) of HLX04 plus HLX10 in patients with advanced solid tumors	PFS determined by RECIST criteria	Day 1 of treatment up to 2 years
Overall Survival (OS) of HLX04 plus HLX10 in patients with advanced solid tumors	OS determined by RECIST criteria	Day 1 of treatment up to 2 years
Immunogenicity	Anti-drug Antibody (ADA) Testing	Day 1 of treatment up to 2 years

Collaborators and Investigators

• Sponsor: Shanghai Henlius Biotech

Study record dates

Study Major Dates

• Study Start (ACTUAL): November 27, 2018
• Primary Completion (ANTICIPATED): September 27, 2019
• Study Completion (ANTICIPATED): December 27, 2020

Study Registration Dates

• First Submitted: November 19, 2018
• First Submitted That Met QC Criteria: November 27, 2018
• First Posted (ACTUAL): November 29, 2018

Study Record Updates

• Last Update Posted (ACTUAL): May 23, 2019
• Last Update Submitted That Met QC Criteria: May 22, 2019
• Last Verified: May 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: HLX10HLX04-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No